Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis

Y K Loke, C S Kwok, J M Wong, P Sankaran, P K Myint

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background
We aimed to determine whether patients with concomitant community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD) are at greater risk of death when compared with those with CAP or acute COPD exacerbation alone. We also assessed the effect of inhaled corticosteroids (ICS) on pneumonia mortality in COPD.
Methods
We searched MEDLINE and EMBASE from inception to March 2012 for studies reporting on mortality in patients with COPD and CAP. We assessed ascertainment of disease, mortality, drug exposure and adjustment for confounders. Data were pooled using random effects meta-analysis, and heterogeneity was estimated using I2.
Results
We identified 24 eligible articles overall. Evaluation of 13 studies revealed considerable heterogeneity and a non-significant mortality risk associated with concomitant COPD and CAP as compared with CAP in five studies that reported adjusted or severity-matched data, pooled RR 1.44 (95% CI 0.97–2.16, I2 = 50%). There was also considerable inconsistency amongst the effect estimates from five studies that reported on the associated mortality with concomitant CAP and COPD as compared with acute COPD exacerbations alone. Evaluation of six datasets found that ICS use in COPD was not consistently associated with lower mortality in CAP. Reports of reduced mortality with prior ICS use stemmed from three studies that enrolled participants from the same healthcare database.
Conclusions
Evidence on associated mortality risk with concomitant CAP and COPD (as opposed to CAP alone, or COPD exacerbation alone) is weak and heterogeneous. ICS use was not consistently associated with reduced mortality from pneumonia.
Original languageEnglish
Pages (from-to)477-487
Number of pages11
JournalInternational Journal of Clinical Practice
Volume67
Issue number5
Early online date11 Apr 2013
DOIs
Publication statusPublished - May 2013

Fingerprint

Chronic Obstructive Pulmonary Disease
Meta-Analysis
Pneumonia
Mortality
Adrenal Cortex Hormones
Disease Progression
MEDLINE
Databases
Delivery of Health Care

Keywords

  • Administration, Inhalation
  • Adult
  • Aged
  • Cohort Studies
  • Community-Acquired Infections
  • Female
  • Glucocorticoids
  • Humans
  • Male
  • Middle Aged
  • Pneumonia
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory System Agents
  • Risk Factors

Cite this

Chronic obstructive pulmonary disease and mortality from pneumonia : meta-analysis. / Loke, Y K; Kwok, C S; Wong, J M; Sankaran, P; Myint, P K.

In: International Journal of Clinical Practice, Vol. 67, No. 5, 05.2013, p. 477-487.

Research output: Contribution to journalArticle

Loke, Y K ; Kwok, C S ; Wong, J M ; Sankaran, P ; Myint, P K. / Chronic obstructive pulmonary disease and mortality from pneumonia : meta-analysis. In: International Journal of Clinical Practice. 2013 ; Vol. 67, No. 5. pp. 477-487.
@article{881b07b4d68745d386229f9b344c1502,
title = "Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis",
abstract = "Background We aimed to determine whether patients with concomitant community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD) are at greater risk of death when compared with those with CAP or acute COPD exacerbation alone. We also assessed the effect of inhaled corticosteroids (ICS) on pneumonia mortality in COPD. Methods We searched MEDLINE and EMBASE from inception to March 2012 for studies reporting on mortality in patients with COPD and CAP. We assessed ascertainment of disease, mortality, drug exposure and adjustment for confounders. Data were pooled using random effects meta-analysis, and heterogeneity was estimated using I2. Results We identified 24 eligible articles overall. Evaluation of 13 studies revealed considerable heterogeneity and a non-significant mortality risk associated with concomitant COPD and CAP as compared with CAP in five studies that reported adjusted or severity-matched data, pooled RR 1.44 (95{\%} CI 0.97–2.16, I2 = 50{\%}). There was also considerable inconsistency amongst the effect estimates from five studies that reported on the associated mortality with concomitant CAP and COPD as compared with acute COPD exacerbations alone. Evaluation of six datasets found that ICS use in COPD was not consistently associated with lower mortality in CAP. Reports of reduced mortality with prior ICS use stemmed from three studies that enrolled participants from the same healthcare database. Conclusions Evidence on associated mortality risk with concomitant CAP and COPD (as opposed to CAP alone, or COPD exacerbation alone) is weak and heterogeneous. ICS use was not consistently associated with reduced mortality from pneumonia.",
keywords = "Administration, Inhalation, Adult, Aged, Cohort Studies, Community-Acquired Infections, Female, Glucocorticoids, Humans, Male, Middle Aged, Pneumonia, Pulmonary Disease, Chronic Obstructive, Respiratory System Agents, Risk Factors",
author = "Loke, {Y K} and Kwok, {C S} and Wong, {J M} and P Sankaran and Myint, {P K}",
note = "{\circledC} 2013 Blackwell Publishing Ltd.",
year = "2013",
month = "5",
doi = "10.1111/ijcp.12120",
language = "English",
volume = "67",
pages = "477--487",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Chronic obstructive pulmonary disease and mortality from pneumonia

T2 - meta-analysis

AU - Loke, Y K

AU - Kwok, C S

AU - Wong, J M

AU - Sankaran, P

AU - Myint, P K

N1 - © 2013 Blackwell Publishing Ltd.

PY - 2013/5

Y1 - 2013/5

N2 - Background We aimed to determine whether patients with concomitant community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD) are at greater risk of death when compared with those with CAP or acute COPD exacerbation alone. We also assessed the effect of inhaled corticosteroids (ICS) on pneumonia mortality in COPD. Methods We searched MEDLINE and EMBASE from inception to March 2012 for studies reporting on mortality in patients with COPD and CAP. We assessed ascertainment of disease, mortality, drug exposure and adjustment for confounders. Data were pooled using random effects meta-analysis, and heterogeneity was estimated using I2. Results We identified 24 eligible articles overall. Evaluation of 13 studies revealed considerable heterogeneity and a non-significant mortality risk associated with concomitant COPD and CAP as compared with CAP in five studies that reported adjusted or severity-matched data, pooled RR 1.44 (95% CI 0.97–2.16, I2 = 50%). There was also considerable inconsistency amongst the effect estimates from five studies that reported on the associated mortality with concomitant CAP and COPD as compared with acute COPD exacerbations alone. Evaluation of six datasets found that ICS use in COPD was not consistently associated with lower mortality in CAP. Reports of reduced mortality with prior ICS use stemmed from three studies that enrolled participants from the same healthcare database. Conclusions Evidence on associated mortality risk with concomitant CAP and COPD (as opposed to CAP alone, or COPD exacerbation alone) is weak and heterogeneous. ICS use was not consistently associated with reduced mortality from pneumonia.

AB - Background We aimed to determine whether patients with concomitant community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD) are at greater risk of death when compared with those with CAP or acute COPD exacerbation alone. We also assessed the effect of inhaled corticosteroids (ICS) on pneumonia mortality in COPD. Methods We searched MEDLINE and EMBASE from inception to March 2012 for studies reporting on mortality in patients with COPD and CAP. We assessed ascertainment of disease, mortality, drug exposure and adjustment for confounders. Data were pooled using random effects meta-analysis, and heterogeneity was estimated using I2. Results We identified 24 eligible articles overall. Evaluation of 13 studies revealed considerable heterogeneity and a non-significant mortality risk associated with concomitant COPD and CAP as compared with CAP in five studies that reported adjusted or severity-matched data, pooled RR 1.44 (95% CI 0.97–2.16, I2 = 50%). There was also considerable inconsistency amongst the effect estimates from five studies that reported on the associated mortality with concomitant CAP and COPD as compared with acute COPD exacerbations alone. Evaluation of six datasets found that ICS use in COPD was not consistently associated with lower mortality in CAP. Reports of reduced mortality with prior ICS use stemmed from three studies that enrolled participants from the same healthcare database. Conclusions Evidence on associated mortality risk with concomitant CAP and COPD (as opposed to CAP alone, or COPD exacerbation alone) is weak and heterogeneous. ICS use was not consistently associated with reduced mortality from pneumonia.

KW - Administration, Inhalation

KW - Adult

KW - Aged

KW - Cohort Studies

KW - Community-Acquired Infections

KW - Female

KW - Glucocorticoids

KW - Humans

KW - Male

KW - Middle Aged

KW - Pneumonia

KW - Pulmonary Disease, Chronic Obstructive

KW - Respiratory System Agents

KW - Risk Factors

U2 - 10.1111/ijcp.12120

DO - 10.1111/ijcp.12120

M3 - Article

VL - 67

SP - 477

EP - 487

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 5

ER -